✦ LIBER ✦

Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study

✍ Scribed by Cortelezzi, A; Pasquini, M C; Gardellini, A; Gianelli, U; Bossi, A; Reda, G; Sarina, B; Musto, P; Barcellini, W; Neri, A

Book ID: 109886896
Publisher: Nature Publishing Group
Year: 2009
Tongue: English
Weight: 163 KB
Volume: 23
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2009.148

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bendamustine plus mitoxantrone for relap

Bendamustine plus mitoxantrone for relapsed/refractory chronic lymphocytic leukaemia (CLL): results of a multicentre phase II study of the German CLL Study Group (GCLLSG)

✍ Hubert Köppler; Harald Fuss; Hans J. Hurtz; Owe Knigge; Christoph Losem; Daniel 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB

Subcutaneous Alemtuzumab in Fludarabine-

Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group

✍ Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Schlenk, R. F.; Groner, S.; 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 170 KB

Subcutaneous Alemtuzumab in Fludarabine-

✍ Stilgenbauer, S.; Zenz, T.; Winkler, D.; Buhler, A.; Schlenk, R. F.; Groner, S.; 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 170 KB

## Purpose The phase II CLL2H trial evaluated safety and efficacy of subcutaneous alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). Clinical and biologic markers were evaluated for their impacts on outcome. ## Patients and Methods One hundred nine patients

An Italian retrospective study on the ro

An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients

✍ Agostino Cortelezzi; Giuseppe Gritti; Luca Laurenti; Antonio Cuneo; Stefania Cio 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 173 KB

5.44 Consolidation Therapy with Subcutan

5.44 Consolidation Therapy with Subcutaneous Alemtuzumab after Induction Treatment with Oral Fludarabine and Cyclophosphamide in Previously Untreated Patients Aged 65-70 years with Advanced Stage CLL: Final Results of a Phase II Study from the French Cooperative Group on Chronic Lymphocytic Leukemia and Waldenstrom Macroglobulinemia (FCG-CLL/WM)

✍ Alain Delmer; Olivier Tournilhac; Stéphane Leprêtre; Bruno Cazin; Pierre Feugier 📂 Article 📅 2011 🏛 Elsevier 🌐 English ⚖ 113 KB